Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Eur J Ophthalmol ; 17(1): 75-83, 2007.
Article in English | MEDLINE | ID: mdl-17294386

ABSTRACT

PURPOSE: This study was designed to evaluate the frequency and nature of neovascularization in age-related macular degeneration (ARMD) utilizing the combination of digital imaging techniques, fluorescein angiography (FA), indocyanine green (ICG) angiography, and optical coherence tomography (OCT). METHODS: A complete clinical examination was performed on 100 eyes of 93 consecutive newly diagnosed patients with neovascular ARMD. Digital fluorescein angiography, ICG angiography, and OCT were also used in evaluating those patients. Comparison of the imaging techniques to determine their value in studying the nature of the lesions. RESULTS: On the basis of existing fluorescein standards, 15 eyes were diagnosed with classic choroidal neovascularization (CNV), 15 with minimally classic CNV, and 70 with occult CNV. ICG angiography was superior for detecting the active vascular component in polypoidal CNV (16 eyes) and retinal angiomatous proliferation (14 eyes). OCT was more sensitive than FA for determining the presence of cystoid macular edema evident in the vast majority of eyes with retinal angiomatous proliferation (RAP). CONCLUSIONS: These results suggest that FA, ICG angiography, and OCT, when used in combination, will assist clinicians in best determining the precise nature of the neovascular process in ARMD.


Subject(s)
Choroidal Neovascularization/diagnosis , Coloring Agents , Fluorescein Angiography/methods , Indocyanine Green , Macular Degeneration/diagnosis , Tomography, Optical Coherence/methods , Aged , Aged, 80 and over , Choroid/blood supply , Choroidal Neovascularization/etiology , Female , Humans , Macular Degeneration/complications , Male , Middle Aged , Prospective Studies , Retinal Neovascularization/diagnosis , Retinal Neovascularization/etiology , Retinal Vessels/pathology
2.
J Cataract Refract Surg ; 25(3): 357-62, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10079440

ABSTRACT

PURPOSE: To evaluate the efficacy and safety of intracameral recombinant tissue plasminogen activator (rt-PA) application for fibrinolysis of fibrin formation after cataract surgery in children. SETTING: Johann Wolfgang Goethe-University, Department of Ophthalmology, Frankfurt am Main, Germany. METHODS: This study comprised 11 eyes of 10 patients aged 3 to 13 years (mean 7.2 +/- 3.68 [SD]) who developed severe fibrin formation after cataract surgery and IOL implantation despite intensive topical steroid therapy. Under general anesthesia, fibrinolysis was performed with 10 micrograms of rt-PA 7.18 +/- 2.04 days after intraocular surgery. Follow-up included slitlamp examination, tonometry, visual acuity testing, and-ophthalmoscopy. Anterior chamber flare measurements could be performed in 6 eyes. RESULTS: Complete resolution of fibrin formations occurred in 90% of the patients in these cases, no recurrent fibrinous reaction or adverse effects were noted. In 2 eyes of the same patient with a history of juvenile rheumatoid arthritis and chronic uveitis, fibrin clot dissolution was incomplete. A recurrent fibrinous formation could be observed after 2 and 4 weeks, respectively. A beginning band keratopathy excluding the central and limbal cornea was noted after 6 and 8 weeks, respectively. CONCLUSION: Intraocular application of rt-PA appears to be a safe and efficacious therapeutic approach in the management of severe fibrinous reactions after pediatric cataract surgery.


Subject(s)
Cataract Extraction , Fibrin/drug effects , Fibrinolysis/drug effects , Fibrinolytic Agents/therapeutic use , Postoperative Complications/drug therapy , Tissue Plasminogen Activator/therapeutic use , Adolescent , Anterior Chamber , Cataract Extraction/adverse effects , Child , Child, Preschool , Female , Fibrinolytic Agents/administration & dosage , Follow-Up Studies , Humans , Lens Implantation, Intraocular , Male , Pilot Projects , Postoperative Complications/pathology , Recombinant Proteins/administration & dosage , Recombinant Proteins/therapeutic use , Safety , Tissue Plasminogen Activator/administration & dosage , Treatment Outcome , Visual Acuity
SELECTION OF CITATIONS
SEARCH DETAIL
...